QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.

Understanding the impact of induction and maintenance therapy on patients' quality of life (QoL) is important for treatment selection. This study aims to compare patient-reported QoL between patients treated with KTd or KRd induction therapy and K maintenance therapy or observation. QoL was assessed using the EORTC QOL-C 30 and QOL-MY20 questionnaires in the AGMT-02 study, in which 123 patients with newly diagnosed transplant ineligible multiple myeloma were randomized to nine cycles of either KTd or KRd induction therapy, followed by 12 cycles of K maintenance therapy, or observation. Longitudinal assessments showed statistically significant improvements in global health-related QoL, various disease symptoms and pain for both treatment regimens. KTd improved insomnia and fatigue, and KRd improved physical functioning. Cross-sectional comparisons indicated a "slight" superiority of KTd over KRd in several scales, with the exception of higher neuropathy scores with KTd. During maintenance, longitudinal comparisons showed no statistically significant changes. Cross-sectional comparisons revealed a "slight" improvement in cognitive functioning during carfilzomib therapy, but a worsening in most other QoL scales. Induction therapy led to improvements in most QoL items, while maintenance therapy with K maintenance was associated with "slight" or "moderate" impairments in several QoL scales compared with the observation group.

Informations de copyright

© 2024 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

The study was supported by AMGEN which provided support for the conduct and analysis of the trial, and by the Austrian Forum against Cancer which supported in part the scientific assistance of HL. HL declares receiving honoraria for lectures or advisory boards from Janssen, BMS, Takeda, Pfizer, Sanofi, and Stem line and research support from AMGEN and Sanofi. TM received honoraria from AbbVie and BMS. MS received honoraria from Janssen, AbbVie, BMS, and Pfizer. BH received honoraria from BMS, Amgen, AbbVie, and Janssen‐Cilag. KP received research funding and honoraria for consultancy from Amgen, BMS, Janssen, and Roche. WW is an employee of syndena GmbH and received research funding from Amgen, Takeda, BMS‐Celgene, Janssen‐Cilag, Novartis, Roche, Sanofi, and oncotyrol and received honoraria for participation in steering and safety committees from Amgen, BMS‐Celgene, and Morphosys and received honoraria for consultancy from Amgen, Takeda, BMS‐Celgene, EUSA Pharma, Gilead, AbbVie, Janssen‐Cilag, GSK, Incyte, Kite, Novartis, Morphosys, Merck, Pfizer, Roche, Sandoz, and Sanofi, and received honoraria from Fujimoto and Myelom‐ und Lymphomselbsthilfe. MTK received research funding from Janssen and honoraria from GSK, Sanofi, Pfizer, Janssen, Amgen, BMS‐Celgene, and Takeda. AP received honoraria for participation in advisory boards from Novartis, Kite‐Gilead, Amgen, Celgene, Janssen, Roche, Sandoz, AstraZeneca, AbbVie, Takeda, Sanofi, Pfizer, Saegen, Daiichi Sankyo, and received travel support from Kite‐Gilead, Janssen, Roche, AstraZeneca, Pfizer, and Daiichi Sankyo. CS received research funding from AstraZeneca, Janssen‐Cilag, and Roche, and received honoraria for consultancy from AbbVie, AstraZeneca, BMS‐Celgene, Janssen‐Cilag, Roche, and Takeda. SMS received honoraria for consultancy from Jazz Pharmaceuticals, Novartis, Amgen, BMS, and Gilead. HA received research funding from Janssen and received honoraria from Janssen, Amgen, BMS, and Takeda. SK received honoraria from Amgen, BMS‐Celgene, and Sanofi, and received travel grants from BMS and Sobi. RG received research funding, travel support, and honoraria for consultancy and participation in advisory boards from AbbVie, Takeda, Daiichi Sankyo, Gilead, MSD Merck, BMS‐Celgene, Novartis, AstraZeneca, Janssen‐Cilag, and Hoffmann‐La Roche. The remaining authors declare no conflict of interest.